Back to results
US 2002/0164788 A1Published application
Humanized antibodies to CD38
AssigneeThe Wellcome Foundation Limited
InventorsJonathan Henry Ellis, Alan Peter Lewis
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeThe Wellcome Foundation Limited
InventorsJonathan Henry Ellis, Alan Peter Lewis
Estimating the term…
The present invention relates to a monoclonal antibody, preferably with specificity for CD38, having CDRs of foreign origin and a recipient framework region having a sequence of human or primate origin, wherein the original amino acid residues in position 29 and/or 78 of the sequence of the recipient framework region of the heavy chain is replaced by a replacement amino acid residue that is the same or similar to that in the corresponding position of the sequence of the corresponding framework region of the heavy chain of the antibody from which the CDRs are derived. The invention also relates to a method of preparation of the antibody, a pharmaceutical composition containing the antibody and a method of using the antibody for the treatment of cancer and autoimmune diseases.
A monoclonal antibody having donor CDRs of foreign origin and a recipient framework region having a sequence of human or primate origin, wherein the original amino acid residue in position 29 or 78 of the sequence of the recipient framework region of the heavy chain is replaced by a replacement amino acid residue that is the same or similar to that in the corresponding position of the sequence of the corresponding framework region of the heavy chain of the antibody from which the CDRs are derived.
A monoclonal antibody according to any of the preceding claims, wherein the original amino acid residues of the recipient framework region are the same or different and are tyrosine, histidine, tryptophan or 2-phenyl-alanine.
A monoclonal antibody according to any of the preceding claims wherein the recipient framework region is from a heavy chain selected from LES-C, T52, Ab44, HIGI and NEW.
A monoclonal antibody according to any of the preceding claims, wherein the CDRs are of rat, mouse rabbit, or hamster origin.
A monoclonal antibody according to any of the preceding claims, wherein the heavy chain of the antibody from which the CDRs are derived is a murine heavy chain in Kabat groups IB and IIC.
A monoclonal antibody according to any of the preceding claims wherein the antibody binds to CD38.
A monoclonal antibody according to any of the preceding claims, wherein the donor CDR is CDRHI.
A method of producing an antibody according to any of the above claims comprising the steps of:
Use of an antibody according to any of the preceding claims for the treatment of cancer and autoimmune diseases.
Dependencies are inferred from the claim text.